Organization: Health Canada
Year: 2023
Month: January
Request Number: A-2022-001004
Request Summary: Adverse Drug Reactions (ADRs) for C1 Esterase Inhibitor (Human). Report numbers: E2B_05697513, E2B_05662863, E2B_05676847. ADRs for Immunoglobulin (human). Report numbers: E2B_05654955, E2B_05650332, E2B_05626265, E2B_05638123, E2B_05675217. ADR for REPLAGAL. Report number: E2B_05645576. ADR for Lanadelumab. Report number: E2B_05662049.
Disposition: Disclosed in part
Number of pages: 139